Prerpints.org logo
Preprint
Article

This version is not peer-reviewed.

Mdm2-Mediated Ubiquitination Plays a Pivotal Role in Differentiating the Endocytic Roles of GRK2 and Arrestin3

A peer-reviewed version of this preprint was published in:
International Journal of Molecular Sciences 2025, 26(7), 3238. https://doi.org/10.3390/ijms26073238

Submitted:

21 February 2025

Posted:

24 February 2025

You are already at the latest version

Abstract
Upon activation of certain G protein-coupled receptors, Mdm2 promotes the ubiquitination of both GRK2 and arrestin3. Similar to arrestin3, GRK2 ubiquitination was associated with its endocytic activity and proteasomal degradation. Ubiquitination of GRK2 was essential for arrestin3 ubiquitination, and vice versa. Cellular components involved in arrestin3 ubiquitination, including Gβγ, clathrin, and 14-3-3η, were also necessary for GRK2 ubiquitination. Additionally, the arrestin-biased signaling pathway contributed to the ubiquitination of both GRK2 and arrestin3. Using Mdm2-knockdown cells, GRK2 and arrestin3 mutants lacking ubiquitination sites, and receptors deficient in phosphorylation sites, we demonstrated that ubiquitinated GRK2/arrestin3, non-ubiquitinated GRK2, and non-ubiquitinated arrestin3 mediate clathrin-dependent, caveolar, and a third distinct endocytic pathway, respectively. In the context of clathrin-mediated endocytosis, arrestin3’s interaction with clathrin and GRK2’s interaction with the β2-adaptin subunit of adaptor protein complex 2 were critical. These findings suggest that GRK2 and arrestin3 ubiquitination are mutually dependent, with their ubiquitination states determining their roles in distinct endocytic pathways.
Keywords: 
GRK2
;  
Mdm2
;  
ubiquitination
;  
clathrin
;  
endocytosis
;  
14-3-3
Subject: 
Biology and Life Sciences  -   Biochemistry and Molecular Biology

1. Introduction

With agonistic stimulation of most G protein-coupled receptors (GPCRs), for example, dopamine D2 receptor (D2R) and β2 adrenergic receptor (β2AR), the Gα and Gβγ subunit of the cognate heterotrimeric G protein for the receptor dissociates (Gilman, 1987). The released Gβγ subunit along with the phospholipid of the plasma membrane, binds to the PH (pleckstrin homology) domain of GRK2 (GPCR kinase) located in the carboxyl terminus region, resulting in the recruitment of the inactive cytoplasmic GRK2 toward near the plasma membrane where GPCRs bound to the agonist are located (Pitcher et al., 1996; Pitcher et al., 1992; Touhara et al., 1994). This ultimately causes allosteric rearrangement of the AST (active site tether) loop and catalytic domain closure, which are crucial for facilitating its interaction with GPCRs and promoting its catalytic activity towards phosphorylation of the activated receptors (Boguth et al., 2010; Penela et al., 2019).
In addition to allosteric activations, posttranslational modifications observed in the RH domain or C-terminal region also play important roles in the functional regulation of GRK2. For example, when the αN-helix (Tyr13) or RH (regulator of G protein signaling homology) domain (Tyr86, Tyr92) of GRK2 is phosphorylated by c-Src or EGFR (Penela et al., 2001; Sun et al., 2018), the catalytic activity of GRK2 increases. Kinases dependent on second messengers, such as PKA (protein kinase A) and PKC (protein kinase C), also phosphorylate GRK2 and modulate its activity (Houslay and Baillie, 2006; Krasel et al., 2001). GRK2 also undergoes ubiquitination following agonistic stimulation of some GPCRs. Ubiquitination is a series of cellular processes where ubiquitin is attached to the lysine residues of target proteins (Hershko and Ciechanover, 1998). Among the three key enzymes involved in ubiquitination (E1 – E3), the E3 ubiquitin ligase provides substrate selectivity (Ardley and Robinson, 2005). The ubiquitination of GRK2 and arrestin3, crucial components in GPCR regulation, is mediated by Mdm2 (mouse double minute 2 homology), a member of the RING (really interesting new gene) class E3 ligases (Penela et al., 2001; Salcedo et al., 2006; Shenoy et al., 2001; Zhang et al., 2020a).
The ubiquitination and degradation of GRK2 and arrestin3 increase with agonistic stimulation of most GPCRs. Along with this conventional role of ubiquitination, arrestin3 gains endocytic activity via ubiquitination (Shenoy et al., 2001). In contrast, it is not known whether GRK2 also obtains similar functional roles when ubiquitinated via Mdm2.
Previous studies have linked Mdm2-mediated ubiquitination to the proteasomal degradation of GRK2 (Penela et al., 2001), and our pilot studies additionally suggested that it also facilitates the endocytic function of GRK2 on receptors. To investigate this further, we analyzed the mechanism of GRK2 ubiquitination, specifically examining the signaling components involved in comparison with the ubiquitination of arrestin3. We also identified the endocytic pathways and the determining factors adopted by the ubiquitination status of GRK2 and arrestin3.

2. Results

2.1. The Ubiquitination of GRK2 Mediated by Mdm2 Is Associated with Its Endocytic Activity

Unlike the traditional role of ubiquitinating proteins as the proteasomal degradation of the target proteins, Mdm2-mediated ubiquitination of arrestin3 is essential for its endocytic activity. Therefore, we first tested whether the ubiquitination similarly enhances the endocytic activity of GRK2, as it does for arrestin3.
For this, we generated a GRK2 mutant (4KR-GRK2) with key ubiquitination sites (K19, K20, K30, K31) mutated, based on previous studies (Salcedo et al., 2006). Treating cells expressing the dopamine D2 receptor (D2R) with dopamine (DA) resulted in the ubiquitination of WT-GRK2, but not 4KR-GRK2, indicating that the mutation effectively prevents ubiquitination at the targeted sites (Figure 1A). In GRK2-knockdown (KD) cells expressing D2R, receptor endocytosis was more extensively increased with the co-expression of WT-GRK2 compared to 4KR-GRK2 (Figure 1B). These results suggest that GRK2 ubiquitination by Mdm2 is not only involved in the degradation of GRK2, as previously reported (Penela et al., 2001) but also plays a certain role in the receptor endocytic process.

2.2. Arrestin-Biased Signaling Pathway Is Involved in the GRK2 Ubiquitination

It is widely acknowledged that Gβγ subunits, released during GPCR agonist stimulation, and phospholipids from the plasma membrane are crucial for recruiting and activating GRK2 (Pitcher et al., 1996; Pitcher et al., 1992). Contrary to this G protein-dependent activation, studies on the D2R have shown that GRK2 can be recruited independently of G proteins (Pack et al., 2018). Given the requirement of ubiquitination for GRK2 activation, it is likely that GRK2 ubiquitination occurs via an arrestin-biased rather than a G protein-biased signaling pathway.
To elucidate the specific signaling pathways involved in GRK2 ubiquitination, we utilized biased D2R variants and biased D2R agonists. The biased D2R variants, D2G (L125N, Y133L) and D2Arr (A135R, M140D), are known to preferentially signal through G protein and arrestin pathways, respectively (Peterson et al., 2015; Wang et al., 2024). Upon DA treatment, only D2Arr mediated GRK2 ubiquitination, not D2G (Figure 2A). This was further confirmed using biased D2R agonists: DA (balanced), UNC9994 (arrestin-biased)(Allen et al., 2011), and MLS1547 (G protein-biased)(Free et al., 2014). GRK2 ubiquitination was induced by DA and UNC9994, but not by MLS1547 (Figure 2B).
The involvement of the arrestin-biased signaling pathway in GRK2 ubiquitination suggests that arrestin-mediated processes might influence GRK2 ubiquitination.

2.3. Ubiquitination of arrestin3 and GRK2 Is Mutually Related

It has been reported that arrestin is essential for the ubiquitination of GRK2 (Penela et al., 2001)(Figure 3A). In turn, we aimed to determine whether GRK2 is also necessary for the ubiquitination of arrestin3. As illustrated in Figure 3B, knocking down GRK2 inhibited the ubiquitination of arrestin3, indicating that both proteins are needed for their respective ubiquitination.
Mdm2 is responsible for the ubiquitination of both arrestin3 and GRK2, and recent studies have highlighted that the ubiquitination of arrestin3 is crucial for the ubiquitination of GRK2 (Kundu et al., 2024). As shown in Figure 3C, the interaction between GRK2 and Mdm2, which was enhanced following D2R agonist stimulation, was disrupted when cellular arrestins were knocked down. The co-expression of WT-arrestin3 restored the GRK2-Mdm2 interaction, while K11/12R-arrestin3, which does not bind Mdm2 (Shenoy and Lefkowitz, 2005), did not. Conversely, GRK2 knockdown decreased arrestin3 ubiquitination and reduced the interaction between arrestin3 and Mdm2. This effect was reversed by WT-GRK2, but not by 4KR-GRK2, which cannot be ubiquitinated (Figure 3D). These findings indicate that the ubiquitination of GRK2 and arrestin3 is interconnected and that each protein is essential for the other’s ubiquitination.
This interplay between arrestin and GRK2 could be crucial in fine-tuning receptor endocytosis and downstream signaling pathways, highlighting the complex regulatory mechanisms that ensure precise cellular responses to external stimuli.

2.4. Cellular Components Responsible for the Ubiquitination of arrestin3 Are Also Involved in the Ubiquitination of GRK2

Since the ubiquitination of arrestin3 is necessary for the ubiquitination of GRK2, the same components responsible for arrestin3 ubiquitination would also be required for the GRK2 ubiquitination. Prior research has shown several crucial factors involved in arrestin3 ubiquitination (Zhang et al., 2020a). These include clathrin heavy chain (CHC), which is, essential for forming clathrin-coated pits; Gβγ, which recruits GRK2 to activated GPCRs (Pitcher et al., 1992); GRK-mediated receptor phosphorylation, which facilitates receptor endocytosis; and 14-3-3η, which influences receptor endocytosis, recycling, and downstream signaling (Yuan et al., 2019).
Knockdown of CHC, but not caveolin1 (Cav1), inhibited the D2R-mediated GRK2 ubiquitination (Figure 4A). Co-expression of GRK2-CT, which sequesters free Gβγ (Koch et al., 1993), blocked the D2R-mediated GRK2 ubiquitination (Figure 4B). In contrast to WT-β2AR, GRK2-KO-β2AR, whose consensus sites for GRK2-mediated phosphorylation are mutated (Nobles et al., 2011), failed to mediate the β2AR-mediated GRK2 ubiquitination (Figure 4C). Additionally, knockdown of 14-3-3η also prevented the β2AR-mediated GRK2 ubiquitination (Figure 4D).
These results suggest that the ubiquitination of GRK2 is intricately linked to the mechanisms governing arrestin3 ubiquitination. Specifically, components such as clathrin heavy chain, Gβγ, GRK-mediated receptor phosphorylation, and 14-3-3η are crucial for facilitating the ubiquitination process of GRK2, highlighting their broader role in receptor signaling and endocytosis.

2.5. Differential Endocytic Pathways of D2R Are Regulated by the Ubiquitination Status of GRK2 and arrestin3

Our previous findings demonstrated that the CME pathway is associated with ubiquitinated (Ub) forms of arrestin3 and GRK-mediated receptor phosphorylation (Zhang et al., 2020b). Because the ubiquitination of GRK2 is related to the receptor endocytosis (Figure 1) and the ubiquitination of arrestin3 (Figure 3), we investigated whether the ubiquitination status of GRK2 and arrestin3 is related to the different endocytic pathways.
To further investigate the specific endocytic pathways involved in D2R endocytosis mediated by the Ub and non-Ub forms of GRK2 and arrestin3, we employed WT-D2R and a phosphorylation-deficient mutant of D2R (D2R-IC23) and conducted experiments in cells with CHC or Cav1 knockdown (CHC-KD and Cav1-KD) (Figure 5A). In D2R-IC23, all serine and threonine residues in the second and third intracellular loops of D2R were mutated and has been used for the study of phosphorylation-independent processes (Cho et al., 2010). As a result, D2R-IC23 undergoes endocytosis exclusively through non-CME pathways, including caveolar endocytosis and a third distinct non-clathrin-mediated and non-caveolar endocytic route (Zhang et al., 2020b).
In the cells expressing wild-type D2R (WT-D2R), which supports the ubiquitination of GRK2 and arrestin3, D2R endocytosis was inhibited when CHC or Cav1 was knocked down (Figure 5A, compare three WT-D2R groups), suggesting that clathrin-mediated, caveolar, and possibly other pathways are involved in the endocytosis of D2R.
To determine the relationship between specific endocytic pathways and the ubiquitination status of GRK2 and arrestin3, we used D2R-IC23, a receptor variant incapable of inducing GRK2 and arrestin3 ubiquitination (Kundu et al., 2024). The endocytosis of WT-D2R was more extensive than that of D2R-IC23 (Figure 5A, compare the mock groups of WT-D2R and D2R-IC23). WT-D2R endocytosis was inhibited by the knockdown of either CHC or Cav1 (Figure 5A, Mock/WT-D2R), whereas D2R-IC23 endocytosis was blocked by Cav1 knockdown but remained unaffected by CHC knockdown (Figure 5A, Mock/D2R-IC23). These findings align with the framework in Figure 5B, which suggests that WT-D2R endocytosis involves both clathrin-mediated and caveolar pathways and is mediated by both ubiquitinated and non-ubiquitinated forms of GRK2 and arrestin3. In contrast, D2R-IC23, which undergoes non-clathrin-mediated endocytosis (Zhang et al., 2020b), is internalized through non-ubiquitinated GRK2 and arrestin3.
GRK2-mediated enhancement of D2R-IC23 endocytosis was unaffected by CHC knockdown but was almost completely abolished in Cav1-KD cells (Figure 5A, D2R-IC23, GRK2 groups). Similarly, arrestin3-mediated enhancement of D2R-IC23 endocytosis was not impacted by CHC knockdown. However, unlike GRK2, arrestin3’s effect persisted in Cav1-KD cells.
These findings reveal that endocytic pathway selection is governed by the ubiquitination status of GRK2 and arrestin3. Ubiquitinated forms predominantly mediate CME, while non-Ub GRK2 mediates caveolar endocytosis. Distinctively, non-Ub arrestin3 mediates a third endocytic pathway that is non-CME and non-caveolar endocytosis (Figure 5C).

2.6. Mdm2-Mediated Ubiquitination Is Involved in the Clathrin-Mediated Endocytosis of Dopamine D2 Receptor and β2 Adrenoceptor

The conclusion that non-ubiquitinated GRK2 and non-ubiquitinated arrestin3 facilitate caveolar endocytosis and a third distinct endocytic pathway was derived from experiments involving the overexpression of GRK2 and arrestin3. This conclusion was further validated through knockdown studies targeting CHC, Cav1, Mdm2, GRK2, or arrestins. Additionally, we aimed to determine whether the principles established from D2R endocytosis could also apply to the endocytosis of β2AR.
In the Con-KD cells, CME, caveolar endocytosis, and a 3rd endocytic route are available; both Ub and non-Ub GRK2 and arrestin3 are available (refer to Figure 5B). In the Con-KD cells, the endocytosis of β2AR was reduced by about half following treatment with 3 mM MβCD or co-expression of epsin (204-458) that specifically blocks the CME. These observations suggest that both clathrin-mediated and caveolar endocytic pathways, and possibly a 3rd endocytic path are involved in the endocytosis of β2AR.
In the CHC-KD cells, caveolar and a 3rd endocytic pathways are available; only non-Ub forms of GRK2 and arrrestin3 are available. As expected, MβCD treatment which blocks caveolar endocytosis inhibited receptor endocytosis, but co-expression of the epsin fragment (204-458), which selectively blocks CME (Guo et al., 2015), did not affect this inhibition.
In the Cav1-KD cells, CME and a 3rd endocytic pathways are available; both Ub and non-Ub forms of GRK2 and arrestin3 are available. As expected, co-expression of the epsin fragment (204-458) inhibited D2R endocytosis, whereas MβCD treatment did not.
Treatment with 10 μM HLI373, an Mdm2 inhibitor, significantly reduced DA-induced endocytosis of the D2R. Notably, this inhibitory effect was nullified by the knockdown of CHC, but remained unchanged with the knockdown of Cav1 (Figure 6B). Considering that neither GRK2 nor arrestin3 is ubiquitinated in the absence of CHC, these results indicate that the ubiquitination of GRK2 and/or arrestin3 is essential for the CME. These results were confirmed with Mdm2-KD cells. As shown in Figure 6C, he co-expression of the epsin (204-458) inhibited the D2R endocytosis in Con-KD cells, but this inhibition was abolished in Mdm2-KD cells. This result reinforces the idea that Mdm2-mediated ubiquitination is crucial for the CME of GPCRs like β2AR or D2R.

2.7. Interdependent Relationship Between GRK2/Arrestin3 Ubiquitination and D2R Endocytic Pathways

Next, the relationship between protein ubiquitination status and specific endocytic pathways was confirmed through a series of knockdown experiments focusing on GRK2 and arrestins. As shown in Figure 7A, treatment with the Mdm2 inhibitor HLI373 lowered D2R endocytosis, but this effect was abolished upon knockdown of either GRK2 or arrestins, suggesting an interdependent relationship between GRK2 and arrestins in ubiquitination-dependent CME of D2R.
Initial characterization revealed that D2R endocytosis involves both CME and caveolar pathways in control conditions (Figure 7B, Con-KD). Given that GRK2 and arrestin3 reciprocally regulate their ubiquitination (Figure 3C,D), we performed sequential knockdowns to delineate their specific roles in endocytic pathway selection. In arrestin-KD cells of Figure 7B, where GRK2 ubiquitination is inhibited and only non-Ub GRK2 is available, D2R endocytosis exhibited selective sensitivity to MβCD, validating that non-Ub GRK2 facilitates caveolar endocytosis. Conversely, in GRK2-KD cells of Figure 7B, where arrestin3 ubiquitination is blocked, D2R endocytosis became resistant to both MDC and MβCD treatments, suggesting that non-Ub arrestin3 mediates neither CME nor caveolar endocytosis but instead facilitates a distinct third endocytic pathway.
To further confirm these outcomes, we conducted rescue experiments using the ubiquitination mutants of GRK2 and arrestin3 (Figure 7C,D). As shown in Figure 7C, the knockdown of GRK2 abolished the sensitivity of D2R endocytosis to MβCD and MDC (compare the Mock groups of Con-KD and GRK2-KD cells). The co-expression of WT-GRK2 restored sensitivity to both MβCD and MDC, indicating the availability of all three endocytic routes. However, expression of non-ubiquitinatable 4KR-GRK2 resulted in sensitivity only to MβCD, consistent with the operation of caveolar and third endocytic pathways through non-Ub GRK2 (Figure 7C).
In contrast to GRK2-KD cells (Figure 7C), where sensitivity to both MβCD and MDC was lost, arrestin knockdown specifically abolished sensitivity to MDC (Figure 7D), indicating that non-ubiquitinated GRK2 plays a key role in caveolar endocytosis. Co-expression of WT-arrestin2, which enables the presence of both Ub and non-Ub forms of GRK2 and arrestins, restored sensitivity to both inhibitors. Conversely, co-expression of the non-ubiquitinatable NLSX-arrestin3, which permits only non-Ub forms of GRK2 and arrestin3, restored sensitivity only to MβCD. This relationship between ubiquitination and receptor endocytic pathways confirms that preventing GRK2 ubiquitination redirects endocytosis toward caveolar and a third distinct pathway, mediated by non-ubiquitinated GRK2 and arrestin3, respectively (Figure 7D).
These findings suggest that ubiquitinated GRK2 and arrestin3 drive clathrin-mediated endocytosis (CME), while their non-ubiquitinated forms mediate distinct pathways—non-ubiquitinated GRK2 facilitates caveolar endocytosis, whereas non-ubiquitinated arrestin3 mediates a separate third pathway (Figure 5C). The reciprocal regulation of ubiquitination between GRK2 and arrestin3 adds a layer of complexity to receptor endocytosis regulation, where changes in the cellular levels of either protein can have broad implications for pathway selection.

2.8. Ubiquitination-Dependent Protein Interactions of arrestin3 and GRK2 Determine Their Selective Contribution to Distinct Endocytic Pathways

Given that the ubiquitination status of GRK2 and arrestin3 determines the selectivity of the endocytic routes they mediate, we examined the relationship between their ubiquitination status and interaction with clathrin and/or Cav1. For this, we examined the interactions between WT and mutants of arrestin3 and GRK2 versus clathrin and/or caveolin1.
Co-immunoprecipitation experiments revealed that WT-arrestin3, which could exist both in Ub form or non-Ub form, interacted with both CHC and Cav1 (Figure 8A, left three lanes), suggesting its role in both CME and caveolar endocytosis. On the other hand, NLSX-arrestin3 which cannot be ubiquitinated (Zhang et al., 2020a), showed no interaction with either protein (4th and 5th lanes), aligning with its role in the third endocytic pathway, which is non-clathrin and non-caveolar. It is not clear at this point whether Ub-arrestin3 mediates caveolar endocytosis as well.
WT-GRK2 demonstrated its binding to CHC at 2 min and Cav1 at 2 and 5 min (Figure 8B, left four lanes), supporting its function in mediating both endocytic pathways. Unlike non-Ub arrestin3, NLSX-arrestin3 which interacted with neither CHC nor Cav1, 4KR-GRK2, a non-Ub form of GRK2, interacted with both CHC and Cav1(right three lanes).
These findings indicate that for arrestin3, the choice between CME and non-CME pathways based on ubiquitination status is influenced by its interaction with the CHC. In contrast, the selective involvement of GRK2 in CME based on its ubiquitination status suggests that its interaction with other proteins could play a critical role.
Adaptor protein complex 2 (AP2 adaptor), which is composed of four subunits, plays a central role in the formation of clathrin-coated vesicles (Kirchhausen, 1999). The clathrin binding site is located on the β2 subunit (β2 adaptin) (Shih et al., 1995), and the interaction between β2 adaptin and GRK2 or arrestin3 was determined. Both the WT- and the non-Ub mutant of arrestin3 (K11/12R) interacted with β2 adaptin (Figure 8C). However, only the WT form of GRK2, and not the non-Ub mutant (4KR-GRK2), interacted with β2 adaptin (Figure 8D). These results highlight distinct mechanisms underlying CME selectivity: arrestin3’s ubiquitination directly governs its interaction with clathrin heavy chain (CHC), while GRK2’s ubiquitination regulates CME via its binding to β2 adaptin.

3. Discussion

This study underscores the multifaceted roles of ubiquitination in the regulation and functionality of GRK2, particularly in its involvement in endocytic pathways of GPCRs. Our findings extend the known regulatory framework governing GRK2 activity and highlight the complex interplay between GRK2 and arrestin3 ubiquitination processes, suggesting a coordinated mechanism that ensures precise cellular responses.
In agreement with traditional aspects of ubiquitination, it has been reported that the ubiquitination of GRK2 plays a role in facilitating its degradation (Salcedo et al., 2006). However, our study provides compelling evidence that Mdm2-mediated ubiquitination of GRK2 extends beyond this conventional role, endocytic activity. This parallels the established role of ubiquitination in enhancing the endocytic activity of arrestin3 (Shenoy et al., 2001), suggesting a similar mechanism for GRK2.
Our results underscore a reciprocal relationship between the ubiquitination of GRK2 and arrestin3. Knockdown of GRK2 or removal of GRK2 ubiquitination prevented the arrestin3 ubiquitination, and vice versa, highlighting a mutual dependency. We also identified shared cellular components governing both GRK2 and arrestin3 ubiquitination, including CHC, Gβγ, receptor phosphorylation, and 14-3-3η (Kundu et al., 2024). The interdependence between GRK2 and arrestin3 ubiquitination and the shared dependency on common cellular machinery underscores the coordinated regulation of GRK2 and arrestin3 ubiquitination. Notably, GRK2 ubiquitination occurs through arrestin-biased rather than G protein-biased signaling, revealing an unexpected layer of regulation in GPCR trafficking.
Our findings reveal complex regulatory mechanisms governing GPCR endocytosis through the interplay of GRK2 and arrestin3 ubiquitination. The data demonstrates three distinct endocytic pathways: clathrin-mediated endocytosis (CME), caveolar endocytosis, and a novel third pathway, each regulated by the ubiquitination status of GRK2 and arrestin3 (Figure 9). Ubiquitinated GRK2 and arrestin3 primarily mediate CME, while their non-Ub forms direct trafficking through alternative pathways - caveolar endocytosis for GRK2 and the third pathway for arrestin3. This pathway selection is further regulated through distinct protein interactions. Arrestin3’s ubiquitination directly controls its binding to CHC and Cav1, while GRK2’s ubiquitination modulates β2 adaptin interaction, suggesting different molecular mechanisms for CME selection.
Identifying a third endocytic pathway, distinct from CME and caveolar endocytosis, adds another layer of complexity to GPCR trafficking regulation. This pathway, mediated by non-Ub arrestin3, provides cells additional flexibility in receptor internalization. The ability to reroute receptor trafficking through alternative pathways when one route is blocked demonstrates the adaptability of the cellular endocytic machinery.
These findings have important implications for cellular signaling regulation. Changes in GRK2 and arrestin3 expression levels or ubiquitination status could significantly alter GPCR trafficking patterns, potentially affecting downstream signaling outcomes. This complex interplay provides cells with precise control over receptor trafficking and may contribute to the diversity of cellular responses to GPCR activation.
Understanding these regulatory mechanisms could have therapeutic implications, particularly for conditions involving dysregulated GPCR signaling. The ability to selectively modulate specific endocytic pathways through manipulation of GRK2 and arrestin3 ubiquitination might offer new therapeutic strategies for such disorders.

4. Materials and Methods

4.1. Materials

Dopamine, isoproterenol, methyl-β-cyclodextrin (MβCD), monodansylcadaverine (MDC), UNC9995, MLS1547, agarose beads coated with monoclonal antibodies against FLAG epitope, rabbit anti-FLAG M2 antibodies (AB_439687), HLI373, an Mdm2 inhibitor, rabbit anti-actin antibody (AB_476694), rabbit 14-3-3η antibody (AB_10747080), and goat anti-mouse (AB_390192) and anti-rabbit (AB_390191) horseradish peroxidase (HRP)-labeled secondary antibodies were sourced from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Mouse monoclonal antibodies targeting the clathrin heavy chain (CHC) (AB_397865) and caveolin1 (Cav1) (AB_397472) were obtained from BD Biosciences (San Jose, CA, USA). Monoclonal antibodies against the HA epitope (AB_783679), GRK2 (AB_626751), and Mdm2 (AB_627920) were procured from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to β-actin (AB_10950489), lamin b1 (AB_10896336), and rabbit 14-3-3η monoclonal antibody (AB_10829034) were obtained from Cell Signaling Technology (Danvers, Massachusetts, USA). [3H]-Sulpiride (84 Ci/mmol) and [3H]-CGP12177 were obtained from PerkinElmer Life Sciences (Boston, MA, USA).

4.2. DNA Constructs

Dopamine D2 receptor (D2R), FLAG-D2R, and D2R-IC23 were reported previously (Cho et al., 2010; Kim et al., 2001). In D2R-IC23, all serine and threonine residues located within the 2nd and 3rd intracellular loops were mutated to alanine and valine residues. Two D2R mutants that preferentially signal through G protein (D2G, L125N/Y133L) or arrestin (D2Arr, A135R/M140D) were previously reported (Peterson et al., 2015). A mutant of GRK2 deficit of Mdm2-mediated ubiquitination sites (4KR-GRK2, L19,20,30, 31R)(Salcedo et al., 2006) was prepared by site-directed mutagenesis. FLAG-D2Arr and FLAG-D2G were prepared by polymerase cycle reaction. GRK2-CT and FLAG-β2 adaptin were described previously (Koch et al., 1994; Laporte et al., 2002). β2 Adrenergic receptor, GRK2, FLAG-GRK2, arrestin3, FLAG-arrestin3, K11/12R-arrestin3, NLSX-arrestin3, arrestin3-GFP, FLAG-Mdm2, and HA-Ub were described previously (Guo et al., 2015; Kim et al., 2001; Wang et al., 2024).

4.3. Cell Culture

Human embryonic kidney (HEK-293) cells were sourced from the American Type Culture Collection (Manassas, VA, USA) and cultured in minimal essential medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin in a humidified atmosphere with 5% CO2. Mdm2-knockdown (KD) cells, GRK2-KD cells, CHC-KD cells, Cav1-KD cells, and 14-3-3η-KD cells were maintained following previously established protocols (Guo et al., 2015; Min et al., 2013; Sun et al., 2017; Zheng et al., 2015). Arrestin2-KD and arrestin3-KD cells were established through stable transfection of the shRNA of arrestin2 in pLKO.1 (Santa Cruz Biotechnology) and the shRNA in pcDNA3.0 (Cho et al., 2010). Arrestin2/3-KD cells were established by stable transfection of shRNA of arrestin3 into arrestin2-KD cells.

4.4. Immunoprecipitation and Immunoblotting

Cells were rinsed with phosphate-buffered saline (PBS) and lysed using RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 1% NP-40, 0.5% deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)) for 1 hour at 4°C with gentle agitation. The cell lysates were then centrifuged for 30 min at 14,000 × g, and the supernatants were combined with 35 μL of agarose beads coated with antibodies against FLAG (50% slurry) for 2–3 hours at 4°C with gentle agitation. Subsequently, the beads were washed three times with ice-cold washing buffer (50 mM Tris pH 7.4, 137 mM NaCl, 10% glycerol, and 1% NP-40) for 5 minutes each, and sodium dodecyl sulfate (SDS) buffer was added. The immunoprecipitates were subjected to SDS polyacrylamide gel electrophoresis (PAGE) using a 5% stacking gel and a 10% separation gel, followed by transfer to nitrocellulose membranes (GE Healthcare Life Sciences; Chicago, IL, USA). The membranes were blocked by incubating with 5% non-fat dry milk in TBS-T (Tris-buffered saline with Tween™ 20) at 20°C for 2–5 hours. They were then washed with TBS-T for 15 minutes at 20°C. Next, the membranes were incubated with primary antibodies dissolved in 2% BSA in TBS-T (1:2000 dilution) for 2 hours at 20°C or overnight at 4°C. After another 15-minute wash with TBS-T, the membranes were incubated with the corresponding HRP-conjugated secondary antibodies dissolved in 2% BSA (1:3000 dilution) for 1 hour at 20°C. Protein bands were visualized and quantified using the ChemiDoc MP imaging system (BioRad, Hercules, California, USA).

4.5. Detection of Protein Ubiquitination

HEK-293 cells expressing D2R were transfected with HA-ubiquitin (HA-Ub) along with FLAG-tagged GRK2 or arrestin3. After 4–6 hours of serum starvation, the cells were treated with 10 μM DA for 2 min. Cell lysates were prepared using lysis buffer containing 150 mM NaCl, 50 mM Tris pH 7.4, 1 mM EDTA, 1% Triton X-100, 10% (v/v) glycerol, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 2 mM phenylmethylsulfonyl fluoride, 5 μg/mL leupeptin, 5 μg/mL aprotinin, and 10 mM N-ethylmaleimide. Immunoprecipitation was performed using FLAG beads, and the immunoprecipitates were subsequently analyzed by SDS-PAGE and probed with antibodies against HA and FLAG.

4.6. Receptor Endocytosis

Endocytosis of D2R and β2AR was assessed using the hydrophilic properties of [3H]-sulpiride and [3H]-CGP12177, respectively, as previously described (Guo et al., 2015; Kim et al., 2001). HEK-293 cells expressing D2R or β2AR were seeded at a density of 1.5 × 105 cells per well in 24-well plates one day after transfection. The following day, cells were rinsed once and pre-incubated for 15 min with 0.5 mL pre-warmed serum-free medium containing 10 mM HEPES (pH 7.4) at 37°C. Subsequently, the cells were stimulated with 10 μM DA or ISO for 1 hour and 20 minutes, respectively. Afterward, cells were incubated with 250 μL of [3H]-sulpiride (2.2 nM) or [3H]-CGP12177 (10 nM) at 4°C for 150 min in the presence or absence of an unlabeled competitive inhibitor (10 μM haloperidol or propranolol). Following incubation, the cells were washed three times with the same medium, and 1% SDS was added. Samples were mixed with 2 mL scintillation fluid and counted using a liquid scintillation analyzer (Perkin Elmer, 1450 MicroBeta TriLux, Waltham, MA, USA).

4.7. Statistics

To minimize variation between experiments, the normalized values of immunoblots were averaged and expressed as fold change, with the mean value of the control group set as 1. The Y-axis label in the figures represents the “fold mean of the controls.” The analysis used GraphPad Prism 8 software (GraphPad Software Inc., San Diego, CA, USA). Data were expressed as the mean ± SD. Statistical significance was assessed using a paired two-tailed Student’s t-test for two groups or one-way ANOVA with Tukey’s post hoc test for multiple groups. The post hoc tests were conducted only if the F value in ANOVA achieved a significance level of p < 0.05 and there was no significant variance inhomogeneity.

5. Conclusions

This study reveals the multifaceted roles of Mdm2-mediated ubiquitination of GRK2, demonstrating that it not only facilitates the degradation of GRK2 but also plays a critical role in regulating its endocytic activity. Importantly, the ubiquitination of GRK2 and arrestin3 is shown to involve shared molecular factors, highlighting an interdependent relationship between these two proteins. Moreover, the findings suggest that the arrestin-biased signaling pathway is involved in the ubiquitination of GRK2, adding a new layer of complexity to the regulation of these processes. The study further underscores the role of ubiquitination status in dictating the specific endocytic pathways mediated by GRK2 and arrestin3 based on their ubiquitination status. Ubiquitination-dependent selective interactions with key adaptor proteins, such as clathrin heavy chain or β2 adaptin, are shown to be pivotal in determining the choice of endocytic routes. Collectively, these results provide critical insights into the intricate regulatory mechanisms of GPCRs, emphasizing the sophisticated interplay between ubiquitination, endocytosis, and signaling

Author Contributions

D.K., X.M., X.Z., X.T., S.W.: investigation, data analysis. K.M.K.: design of the experiments and writing. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (RS-2023-00239943).

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author.

Acknowledgments

We thank the Korea Basic Science Institute for its technical support. We thank Professor Somy Yoon (College of Pharmacy, Chonnam National University) for her help with image analysis.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Allen, J.A., J.M. Yost, V. Setola, X. Chen, M.F. Sassano, M. Chen, S. Peterson, P.N. Yadav, X.P. Huang, B. Feng, N.H. Jensen, X. Che, X. Bai, S.V. Frye, W.C. Wetsel, M.G. Caron, J.A. Javitch, B.L. Roth, and J. Jin. 2011. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 108:18488-18493. [CrossRef]
  2. Ardley, H.C., and P.A. Robinson. 2005. E3 ubiquitin ligases. Essays Biochem. 41:15-30.
  3. Boguth, C.A., P. Singh, C.C. Huang, and J.J. Tesmer. 2010. Molecular basis for activation of G protein-coupled receptor kinases. EMBO J. 29:3249-3259.
  4. Cho, D., M. Zheng, C. Min, L. Ma, H. Kurose, J.H. Park, and K.M. Kim. 2010. Agonist-induced endocytosis and receptor phosphorylation mediate resensitization of dopamine D(2) receptors. Mol Endocrinol. 24:574-586. [CrossRef]
  5. Free, R.B., L.S. Chun, A.E. Moritz, B.N. Miller, T.B. Doyle, J.L. Conroy, A. Padron, J.A. Meade, J. Xiao, X. Hu, A.E. Dulcey, Y. Han, L. Duan, S. Titus, M. Bryant-Genevier, E. Barnaeva, M. Ferrer, J.A. Javitch, T. Beuming, L. Shi, N.T. Southall, J.J. Marugan, and D.R. Sibley. 2014. Discovery and characterization of a G protein-biased agonist that inhibits beta-arrestin recruitment to the D2 dopamine receptor. Mol Pharmacol. 86:96-105. [CrossRef]
  6. Gilman, A.G. 1987. G proteins: transducers of receptor-generated signals. Annu Rev Biochem. 56:615-649. [CrossRef]
  7. Guo, S., X. Zhang, M. Zheng, X. Zhang, C. Min, Z. Wang, S.H. Cheon, M.H. Oak, S.Y. Nah, and K.M. Kim. 2015. Selectivity of commonly used inhibitors of clathrin-mediated and caveolae-dependent endocytosis of G protein-coupled receptors. Biochim Biophys Acta. 1848:2101-2110. [CrossRef]
  8. Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu Rev Biochem. 67:425-479. [CrossRef]
  9. Houslay, M.D., and G.S. Baillie. 2006. Phosphodiesterase-4 gates the ability of protein kinase A to phosphorylate G-protein receptor kinase-2 and influence its translocation. Biochem Soc Trans. 34:474-475. [CrossRef]
  10. Kim, K.M., K.J. Valenzano, S.R. Robinson, W.D. Yao, L.S. Barak, and M.G. Caron. 2001. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem. 276:37409-37414. [CrossRef]
  11. Kirchhausen, T. 1999. Adaptors for clathrin-mediated traffic. Annu Rev Cell Dev Biol. 15:705-732. [CrossRef]
  12. Koch, W.J., B.E. Hawes, J. Inglese, L.M. Luttrell, and R.J. Lefkowitz. 1994. Cellular expression of the carboxyl terminus of a G protein-coupled receptor kinase attenuates G beta gamma-mediated signaling. J Biol Chem. 269:6193-6197. [CrossRef]
  13. Koch, W.J., J. Inglese, W.C. Stone, and R.J. Lefkowitz. 1993. The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. J Biol Chem. 268:8256-8260. [CrossRef]
  14. Krasel, C., S. Dammeier, R. Winstel, J. Brockmann, H. Mischak, and M.J. Lohse. 2001. Phosphorylation of GRK2 by protein kinase C abolishes its inhibition by calmodulin. J Biol Chem. 276:1911-1915. [CrossRef]
  15. Kundu, D., X. Min, X. Zhang, X. Tian, S. Wang, and K.M. Kim. 2024. The Ubiquitination of Arrestin3 within the Nucleus Triggers the Nuclear Export of Mdm2, Which, in Turn, Mediates the Ubiquitination of GRK2 in the Cytosol. Int J Mol Sci. 25. [CrossRef]
  16. Laporte, S.A., W.E. Miller, K.M. Kim, and M.G. Caron. 2002. beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binging site in beta 2-adaptin. J Biol Chem. 277:9247-9254. [CrossRef]
  17. Min, C., M. Zheng, X. Zhang, M.G. Caron, and K.M. Kim. 2013. Novel roles for beta-arrestins in the regulation of pharmacological sequestration to predict agonist-induced desensitization of dopamine D3 receptors. Br J Pharmacol. 170:1112-1129. [CrossRef]
  18. Nobles, K.N., K. Xiao, S. Ahn, A.K. Shukla, C.M. Lam, S. Rajagopal, R.T. Strachan, T.Y. Huang, E.A. Bressler, M.R. Hara, S.K. Shenoy, S.P. Gygi, and R.J. Lefkowitz. 2011. Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin. Science signaling. 4:ra51. [CrossRef]
  19. Pack, T.F., M.I. Orlen, C. Ray, S.M. Peterson, and M.G. Caron. 2018. The dopamine D2 receptor can directly recruit and activate GRK2 without G protein activation. J Biol Chem. 293:6161-6171. [CrossRef]
  20. Penela, P., A. Elorza, S. Sarnago, and F. Mayor, Jr. 2001. Beta-arrestin- and c-Src-dependent degradation of G-protein-coupled receptor kinase 2. EMBO J. 20:5129-5138. [CrossRef]
  21. Penela, P., C. Ribas, F. Sanchez-Madrid, and F. Mayor, Jr. 2019. G protein-coupled receptor kinase 2 (GRK2) as a multifunctional signaling hub. Cell Mol Life Sci. 76:4423-4446. [CrossRef]
  22. Peterson, S.M., T.F. Pack, A.D. Wilkins, N.M. Urs, D.J. Urban, C.E. Bass, O. Lichtarge, and M.G. Caron. 2015. Elucidation of G-protein and beta-arrestin functional selectivity at the dopamine D2 receptor. Proc Natl Acad Sci U S A. 112:7097-7102. [CrossRef]
  23. Pitcher, J.A., Z.L. Fredericks, W.C. Stone, R.T. Premont, R.H. Stoffel, W.J. Koch, and R.J. Lefkowitz. 1996. Phosphatidylinositol 4,5-bisphosphate (PIP2)-enhanced G protein-coupled receptor kinase (GRK) activity. Location, structure, and regulation of the PIP2 binding site distinguishes the GRK subfamilies. J Biol Chem. 271:24907-24913. [CrossRef]
  24. Pitcher, J.A., J. Inglese, J.B. Higgins, J.L. Arriza, P.J. Casey, C. Kim, J.L. Benovic, M.M. Kwatra, M.G. Caron, and R.J. Lefkowitz. 1992. Role of beta gamma subunits of G proteins in targeting the beta-adrenergic receptor kinase to membrane-bound receptors. Science. 257:1264-1267.
  25. Salcedo, A., F. Mayor, Jr., and P. Penela. 2006. Mdm2 is involved in the ubiquitination and degradation of G-protein-coupled receptor kinase 2. EMBO J. 25:4752-4762. [CrossRef]
  26. Shenoy, S.K., and R.J. Lefkowitz. 2005. Receptor-specific ubiquitination of beta-arrestin directs assembly and targeting of seven-transmembrane receptor signalosomes. J Biol Chem. 280:15315-15324. [CrossRef]
  27. Shenoy, S.K., P.H. McDonald, T.A. Kohout, and R.J. Lefkowitz. 2001. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science. 294:1307-1313. [CrossRef]
  28. Shih, W., A. Gallusser, and T. Kirchhausen. 1995. A clathrin-binding site in the hinge of the beta 2 chain of mammalian AP-2 complexes. J Biol Chem. 270:31083-31090. [CrossRef]
  29. Sun, N., X. Zhang, S. Guo, H.T. Le, X. Zhang, and K.M. Kim. 2018. Molecular mechanisms involved in epidermal growth factor receptor-mediated inhibition of dopamine D3 receptor signaling. Biochim Biophys Acta Mol Cell Res. 1865:1187-1200. [CrossRef]
  30. Sun, N., X. Zhang, X. Zhang, and K.M. Kim. 2017. The EGF receptor inhibits the signaling of dopamine D3 receptor through the phosphorylation of GRK2 on tyrosine residues. Biochem Biophys Res Commun. 489:515-522. [CrossRef]
  31. Touhara, K., J. Inglese, J.A. Pitcher, G. Shaw, and R.J. Lefkowitz. 1994. Binding of G protein beta gamma-subunits to pleckstrin homology domains. J Biol Chem. 269:10217-10220. [CrossRef]
  32. Wang, S., L. Peng, and K.M. Kim. 2024. Biased Dopamine D(2) Receptors Exhibit Distinct Intracellular Trafficking Properties and ERK Activation in Different Subcellular Domains. Biomol Ther (Seoul). 32:56-64.
  33. Yuan, L., S. Barbash, S. Kongsamut, A. Eishingdrelo, T.P. Sakmar, and H. Eishingdrelo. 2019. 14-3-3 signal adaptor and scaffold proteins mediate GPCR trafficking. Sci Rep. 9:11156. [CrossRef]
  34. Zhang, X., X. Min, S. Wang, N. Sun, and K.M. Kim. 2020a. Mdm2-mediated ubiquitination of beta-arrestin2 in the nucleus occurs in a Gbetagamma- and clathrin-dependent manner. Biochem Pharmacol. 178:114049. [CrossRef]
  35. Zhang, X., M. Zheng, and K.M. Kim. 2020b. GRK2-mediated receptor phosphorylation and Mdm2-mediated beta-arrestin2 ubiquitination drive clathrin-mediated endocytosis of G protein-coupled receptors. Biochem Biophys Res Commun. 533:383-390. [CrossRef]
  36. Zheng, M., X. Zhang, S. Guo, X. Zhang, H.J. Choi, M.Y. Lee, and K.M. Kim. 2015. PKCbetaII inhibits the ubiquitination of beta-arrestin2 in an autophosphorylation-dependent manner. FEBS Lett. 589:3929-3937. [CrossRef]
Preprints 150146 g001
Figure 1. Association between Mdm2-mediated ubiquitination of GRK2 and its endocytic activity. (A)HEK-293 cells expressing D2R (between 1.5 – 1.7 pmol/mg protein) were transfected with HA-Ub together with either FLAG-tagged WT- or 4KR-GRK2. Cells were treated with 10 μM DA for 2 min. Cell lysates were immunoprecipitated with FLAG beads and the immunoprecipitates were blotted with antibodies against HA and FLAG to detect the Ub-GRK2 and total GRK2, respectively. **p < 0.01 compared to other groups (n = 3). (B)GRK2-knockdown (KD) HEK-293 cells were transfected with D2R along with a mock vector, WT-GRK2, or 4KR-GRK2. Cells were treated with 10 μM DA for 1 hour, followed by three washes with serum-free media. Cells were treated with 2.2. nM [3H]-sulpiride at 150 min at 4 oC. **p < 0.01, ***p < 0.001 compared to 15 min/Mock group; $$p < 0.01, $$$p < 0.001 compared to 30 min/Mock group; ##p < 0.001 compared to 30 min/Mock group (n = 3). Cell lysates from Con-KD and GRK2-KD cells were immunoblotted with antibodies against GRK2 and actin. The knockout efficiency was about 95%. In addition, the cell lysates obtained from the GRK2-KD cells transfected with a mock vector, WT-GRK2, or 4KR-GRK2 were immunoblotted with antibodies against GRK2 and actin.
Figure 1. Association between Mdm2-mediated ubiquitination of GRK2 and its endocytic activity. (A)HEK-293 cells expressing D2R (between 1.5 – 1.7 pmol/mg protein) were transfected with HA-Ub together with either FLAG-tagged WT- or 4KR-GRK2. Cells were treated with 10 μM DA for 2 min. Cell lysates were immunoprecipitated with FLAG beads and the immunoprecipitates were blotted with antibodies against HA and FLAG to detect the Ub-GRK2 and total GRK2, respectively. **p < 0.01 compared to other groups (n = 3). (B)GRK2-knockdown (KD) HEK-293 cells were transfected with D2R along with a mock vector, WT-GRK2, or 4KR-GRK2. Cells were treated with 10 μM DA for 1 hour, followed by three washes with serum-free media. Cells were treated with 2.2. nM [3H]-sulpiride at 150 min at 4 oC. **p < 0.01, ***p < 0.001 compared to 15 min/Mock group; $$p < 0.01, $$$p < 0.001 compared to 30 min/Mock group; ##p < 0.001 compared to 30 min/Mock group (n = 3). Cell lysates from Con-KD and GRK2-KD cells were immunoblotted with antibodies against GRK2 and actin. The knockout efficiency was about 95%. In addition, the cell lysates obtained from the GRK2-KD cells transfected with a mock vector, WT-GRK2, or 4KR-GRK2 were immunoblotted with antibodies against GRK2 and actin.
Preprints 150146 g001
Preprints 150146 g002
Figure 2. Involvement of arrestin-biased pathway in the Mdm2-mediated GRK2 ubiquitination. (A)HEK-293 cells were transfected with HA-Ub and FLAG-GRK2 together with a mock vector, WT-D2R, D2G, and D2Arr. Cells were treated with 10 μM DA for 2 minutes. **p, ##p < 0.01 compared to other groups except for the DA/D2Arr group and DA/D2R group, respectively (n = 3). (B)HEK-293 cells were transfected with HA-Ub, FLAG-GRK2, and D2R. Cells were treated with 10 μM DA, UNC9994, or MLS1547 for 2 min. **p, ##p < 0.01 compared to other groups except for the UNC9994 group and DA group, respectively (n = 3).
Figure 2. Involvement of arrestin-biased pathway in the Mdm2-mediated GRK2 ubiquitination. (A)HEK-293 cells were transfected with HA-Ub and FLAG-GRK2 together with a mock vector, WT-D2R, D2G, and D2Arr. Cells were treated with 10 μM DA for 2 minutes. **p, ##p < 0.01 compared to other groups except for the DA/D2Arr group and DA/D2R group, respectively (n = 3). (B)HEK-293 cells were transfected with HA-Ub, FLAG-GRK2, and D2R. Cells were treated with 10 μM DA, UNC9994, or MLS1547 for 2 min. **p, ##p < 0.01 compared to other groups except for the UNC9994 group and DA group, respectively (n = 3).
Preprints 150146 g002
Preprints 150146 g003
Figure 3. Ubiquitination of arrestin3 and GRK2 is reciprocally related. (A)Con-KD and arrestin2/3-KD cells were transfected with D2R (1.5 – 1.7 pmol/mg protein), HA-Ub, and FLAG-GRK2. Cells were treated with 10 μM DA for 2 minutes. *p < 0.05, **p < 0.01 compared to DA/Con-KD group (n = 3). (B)Con-KD and GRK2-KD cells were transfected with D2R (1.7 – 2.0 pmol/mg protein), HA-Ub, and FLAG-arrestin3. Cells were treated with 10 μM DA for 2 minutes. *p < 0.05, **p < 0.01 compared to DA/Con-KD group (n = 3). (C)Con-KD and arrestin2/3-KD cells were transfected with D2R (1.5 – 1.7 pmol/mg protein), GRK2, FLAG-Mdm2, together with a mock vector, WT-arrestin3, or K11/12R-arrestin3. Cells were treated with 10 μM DA for 2 minutes. Cell lysates were immunoprecipitated with FLAG beads. Co-IP/lysates and IP were immunoblotted with antibodies against GRK2 and FLAG, respectively. *p, #p < 0.05 compared to other groups except the DA/WT/Arr2/3-KD group and DA/Mock/Con-KD group, respectively (n = 3). (D)Con-KD and GRK2-KD cells were transfected with D2R (1.7 – 2.0 pmol/mg protein), HA-Ub, FLAG-arrestin3, together with a mock vector, WT-GRK2, or 4KR-GRK2. Cells were treated with 10 μM DA for 2 minutes. **p < 0.01 compared to other groups except Veh/WT group; #p < 0.05 compared to DA/WT group (n = 3).
Figure 3. Ubiquitination of arrestin3 and GRK2 is reciprocally related. (A)Con-KD and arrestin2/3-KD cells were transfected with D2R (1.5 – 1.7 pmol/mg protein), HA-Ub, and FLAG-GRK2. Cells were treated with 10 μM DA for 2 minutes. *p < 0.05, **p < 0.01 compared to DA/Con-KD group (n = 3). (B)Con-KD and GRK2-KD cells were transfected with D2R (1.7 – 2.0 pmol/mg protein), HA-Ub, and FLAG-arrestin3. Cells were treated with 10 μM DA for 2 minutes. *p < 0.05, **p < 0.01 compared to DA/Con-KD group (n = 3). (C)Con-KD and arrestin2/3-KD cells were transfected with D2R (1.5 – 1.7 pmol/mg protein), GRK2, FLAG-Mdm2, together with a mock vector, WT-arrestin3, or K11/12R-arrestin3. Cells were treated with 10 μM DA for 2 minutes. Cell lysates were immunoprecipitated with FLAG beads. Co-IP/lysates and IP were immunoblotted with antibodies against GRK2 and FLAG, respectively. *p, #p < 0.05 compared to other groups except the DA/WT/Arr2/3-KD group and DA/Mock/Con-KD group, respectively (n = 3). (D)Con-KD and GRK2-KD cells were transfected with D2R (1.7 – 2.0 pmol/mg protein), HA-Ub, FLAG-arrestin3, together with a mock vector, WT-GRK2, or 4KR-GRK2. Cells were treated with 10 μM DA for 2 minutes. **p < 0.01 compared to other groups except Veh/WT group; #p < 0.05 compared to DA/WT group (n = 3).
Preprints 150146 g003
Preprints 150146 g004
Figure 4. Cellular components responsible for the ubiquitination of GRK2. (A)Con-KD, CHC-KD, Cav1-KD were transfected with D2R (1.5 – 1.9 pmol/mg protein), HA-Ub, and FLAG-GRK2. Cells were treated with 10 μM DA for 2 minutes. **p, ##p < 0.01 compared to other groups except for the DA/Cav1-KD group and DA/Con-KD group, respectively (n = 3). Lysates from Con-KD, CHC-KD, and Cav1-KD cells were immunoblotted with antibodies against CHC/actin and Cav1/actin. The knockdown efficiency of CHC-KD and Cav1-KD cells was about 90-95%. (B)Cells were transfected with D2R (1.7 – 1.9 pmol/mg protein) together with a mock vector or GRK2-CT. Cells were treated with 10 μM DA for 2 minutes. **p < 0.01 compared to other groups (n = 3). (C)Cells were transfected with HA-Ub and FLAG-GRK2 together with a mock vector, WT-β2AR, or GRK2-KO-β2AR (1.7 – 1.9 pmol/mg protein). Cells were treated with 10 μM isoproterenol (ISO) for 2 minutes. **p < 0.01 compared to other groups (n = 3). (D)Con-KD or 14-3-3η-KD cells were transfected with D2R (1.7 – 1.9 pmol/mg protein), HA-Ub, and FLAG-GRK2. Cells were treated with 10 μM DA for 2 minutes. **p < 0.01 compared to other groups (n = 3). Lysates of Con-KD and 14-3-3η-KD cells were blotted with antibodies against 14-3-3η and actin. The knockdown efficiency of 14-3-3η was about 90%.
Figure 4. Cellular components responsible for the ubiquitination of GRK2. (A)Con-KD, CHC-KD, Cav1-KD were transfected with D2R (1.5 – 1.9 pmol/mg protein), HA-Ub, and FLAG-GRK2. Cells were treated with 10 μM DA for 2 minutes. **p, ##p < 0.01 compared to other groups except for the DA/Cav1-KD group and DA/Con-KD group, respectively (n = 3). Lysates from Con-KD, CHC-KD, and Cav1-KD cells were immunoblotted with antibodies against CHC/actin and Cav1/actin. The knockdown efficiency of CHC-KD and Cav1-KD cells was about 90-95%. (B)Cells were transfected with D2R (1.7 – 1.9 pmol/mg protein) together with a mock vector or GRK2-CT. Cells were treated with 10 μM DA for 2 minutes. **p < 0.01 compared to other groups (n = 3). (C)Cells were transfected with HA-Ub and FLAG-GRK2 together with a mock vector, WT-β2AR, or GRK2-KO-β2AR (1.7 – 1.9 pmol/mg protein). Cells were treated with 10 μM isoproterenol (ISO) for 2 minutes. **p < 0.01 compared to other groups (n = 3). (D)Con-KD or 14-3-3η-KD cells were transfected with D2R (1.7 – 1.9 pmol/mg protein), HA-Ub, and FLAG-GRK2. Cells were treated with 10 μM DA for 2 minutes. **p < 0.01 compared to other groups (n = 3). Lysates of Con-KD and 14-3-3η-KD cells were blotted with antibodies against 14-3-3η and actin. The knockdown efficiency of 14-3-3η was about 90%.
Preprints 150146 g004
Preprints 150146 g005
Figure 5. Deubiquitinated GRK2 mediates caveolar endocytosis, whereas deubiquitinated arrestin3 facilitates a distinct endocytic pathway independent of clathrin-mediated and caveolar endocytosis. (A)Con-KD, CHC-KD, and Cav1-KD cells were transfected with either WT-D2R and a mock vector or D2R-IC23 along with a mock vector, GRK2, or arrestin3. Cells were treated with 10 µM DA for 1 hour. After three washes, 2.2 nM [³H]-sulpiride was applied for 150 minutes at 4°C. Statistical significance is indicated as follows: ***p < 0.001 compared to the corresponding Con-KD group; ###p < 0.001 compared to the corresponding Con-KD and CHC-KD groups; $$$p < 0.001 compared to the Con-KD cells transfected with GRK2 and Arr3 in the D2R-IC23-expressing condition (n = 3). Cell lysates from each transfection group were analyzed via Western blot using antibodies against GRK2, arrestin, and actin. (B)The ubiquitination status and the available endocytic pathways of D2R in different phosphorylation states of D2R and expression levels of CHC and Cav1. (C) A schematic representation depicting how the ubiquitination status of GRK2 and arrestin3 regulates the selection of specific endocytic pathways.
Figure 5. Deubiquitinated GRK2 mediates caveolar endocytosis, whereas deubiquitinated arrestin3 facilitates a distinct endocytic pathway independent of clathrin-mediated and caveolar endocytosis. (A)Con-KD, CHC-KD, and Cav1-KD cells were transfected with either WT-D2R and a mock vector or D2R-IC23 along with a mock vector, GRK2, or arrestin3. Cells were treated with 10 µM DA for 1 hour. After three washes, 2.2 nM [³H]-sulpiride was applied for 150 minutes at 4°C. Statistical significance is indicated as follows: ***p < 0.001 compared to the corresponding Con-KD group; ###p < 0.001 compared to the corresponding Con-KD and CHC-KD groups; $$$p < 0.001 compared to the Con-KD cells transfected with GRK2 and Arr3 in the D2R-IC23-expressing condition (n = 3). Cell lysates from each transfection group were analyzed via Western blot using antibodies against GRK2, arrestin, and actin. (B)The ubiquitination status and the available endocytic pathways of D2R in different phosphorylation states of D2R and expression levels of CHC and Cav1. (C) A schematic representation depicting how the ubiquitination status of GRK2 and arrestin3 regulates the selection of specific endocytic pathways.
Preprints 150146 g005
Preprints 150146 g006
Figure 6. Mdm2-mediated ubiquitination is needed for the clathrin-mediated endocytosis of dopamine D2 receptor and β2 adrenoceptor. (A)Con-KD, CHC-KD, or Cav1-KD HEK-293 cells were transfected with β2AR (1.6 – 1.9 pmol/mg protein) along with either a mock vector or epsin (204-458). The cells were pretreated with either a vehicle or 3 mM MβCD for 30 minutes, followed by exposure to 10 µM ISO for 20 minutes. After three washes with serum-free media, the cells were treated with 10 nM [3H]-CGP12177 for 150 minutes at 4°C. ***p < 0.001 compared to each Veh-treated group; ###p < 0.001 compared to other groups of Con-KD cells (n = 3). (B)Con-KD, CHC-KD, or Cav1-KD HEK-293 cells were transfected with D2R (1.6 – 1.9 pmol/mg protein). Cells were treated with a Veh or HLI373 for 30 minutes, followed by treatment with 10 μM DA for 1 hour. After three washes with a serum-free media, cells were treated with 2.2 nM [3H]-sulpiride. (C)Con-KD and Mdm2-KD HEK-293 cells were transfected with D2R (1.7 – 1.9 pmol/mg protein) along with a mock vector or epsin (204-458). Cells were treated with a vehicle or 10 μM DA for 1 hour. After three washes with a serum-free media, cells were treated with 2.2 nM [3H]-sulpiride. *p < 0.05, **p < 0.01, ***p < 0.001 compared to Mock/Con-KD cells (n = 3).
Figure 6. Mdm2-mediated ubiquitination is needed for the clathrin-mediated endocytosis of dopamine D2 receptor and β2 adrenoceptor. (A)Con-KD, CHC-KD, or Cav1-KD HEK-293 cells were transfected with β2AR (1.6 – 1.9 pmol/mg protein) along with either a mock vector or epsin (204-458). The cells were pretreated with either a vehicle or 3 mM MβCD for 30 minutes, followed by exposure to 10 µM ISO for 20 minutes. After three washes with serum-free media, the cells were treated with 10 nM [3H]-CGP12177 for 150 minutes at 4°C. ***p < 0.001 compared to each Veh-treated group; ###p < 0.001 compared to other groups of Con-KD cells (n = 3). (B)Con-KD, CHC-KD, or Cav1-KD HEK-293 cells were transfected with D2R (1.6 – 1.9 pmol/mg protein). Cells were treated with a Veh or HLI373 for 30 minutes, followed by treatment with 10 μM DA for 1 hour. After three washes with a serum-free media, cells were treated with 2.2 nM [3H]-sulpiride. (C)Con-KD and Mdm2-KD HEK-293 cells were transfected with D2R (1.7 – 1.9 pmol/mg protein) along with a mock vector or epsin (204-458). Cells were treated with a vehicle or 10 μM DA for 1 hour. After three washes with a serum-free media, cells were treated with 2.2 nM [3H]-sulpiride. *p < 0.05, **p < 0.01, ***p < 0.001 compared to Mock/Con-KD cells (n = 3).
Preprints 150146 g006
Preprints 150146 g007
Figure 7. The ubiquitination of GRK2 and arrestin3 is interdependently linked to the clathrin-mediated endocytosis of the dopamine D2 receptor. (A)Con-KD, arrestin2/3-KD, and GRK2-KD HEK-293 cells were transfected with D2R (1.5 – 1.7 pmol/mg protein). Cells were pretreated with a vehicle or 3 μM HLI373 for 15 hours, followed by 10 μM DA for 1 hour. After three washes with serum-free media, cells were treated with 2.2. nM [3H]-sulpiride for 150 min at 4 oC. ***p < 0.001 compared to other groups (n = 3). (B)Con-KD, arrestin2/3-KD, and GRK2-KD HEK-293 cells were transfected with D2R (1.5 – 1.7 pmol/mg protein). Cells were pretreated with a vehicle, 3 mM MβCD for 30 minutes, or 200 μM MDC for 20 minutes, followed by 10 μM DA for 1 hour. ***p < 0.001 compared to other groups; ##p < 0.01 compared to MβCD/Con-KD cells; $$p < 0.01 compared to the arrestin2/3-KD cells treated with vehicle or MDC (n = 3). (C)Con-KD and GRK2-KD HEK-293 cells were transfected with D2R (1.5 – 1.7 pmol/mg protein) along with a mock vector, WT- or 4KR-GRK2. Cells were pretreated with a vehicle, 3 mM MβCD for 30 minutes, or 200 μM MDC for 20 minutes, followed by treatment with 10 μM DA for 1 hour. ***p < 0.001 compared to the Con-KD cells treated with a vehicle; ###p < 0.001 compared to the cells transfected with WT-GRK2 and treated with vehicle; $$$p < 0.001 compared to other 4KR-GRK2 groups (n = 3). (D)Con-KD and arrestin2/3-KD HEK-293 cells were transfected with D2R (1.5 – 1.7 pmol/mg protein) along with a mock vector, WT- or NLSX-arrestin3. Cells were pretreated with a vehicle, 3 mM MβCD for 30 minutes, or 200 μM MDC for 20 minutes, followed by treatment with 10 μM DA for 1 hour. ***p < 0.001 compared to vehicle-treated group of Con-KD cells; ##p < 0.01 compared to the vehicle-treated cells expressing WT-arrestin3; $p < 0.05, $$p < 0.01 compared to corresponding vehicle- and MDC-treated cells (n = 3).
Figure 7. The ubiquitination of GRK2 and arrestin3 is interdependently linked to the clathrin-mediated endocytosis of the dopamine D2 receptor. (A)Con-KD, arrestin2/3-KD, and GRK2-KD HEK-293 cells were transfected with D2R (1.5 – 1.7 pmol/mg protein). Cells were pretreated with a vehicle or 3 μM HLI373 for 15 hours, followed by 10 μM DA for 1 hour. After three washes with serum-free media, cells were treated with 2.2. nM [3H]-sulpiride for 150 min at 4 oC. ***p < 0.001 compared to other groups (n = 3). (B)Con-KD, arrestin2/3-KD, and GRK2-KD HEK-293 cells were transfected with D2R (1.5 – 1.7 pmol/mg protein). Cells were pretreated with a vehicle, 3 mM MβCD for 30 minutes, or 200 μM MDC for 20 minutes, followed by 10 μM DA for 1 hour. ***p < 0.001 compared to other groups; ##p < 0.01 compared to MβCD/Con-KD cells; $$p < 0.01 compared to the arrestin2/3-KD cells treated with vehicle or MDC (n = 3). (C)Con-KD and GRK2-KD HEK-293 cells were transfected with D2R (1.5 – 1.7 pmol/mg protein) along with a mock vector, WT- or 4KR-GRK2. Cells were pretreated with a vehicle, 3 mM MβCD for 30 minutes, or 200 μM MDC for 20 minutes, followed by treatment with 10 μM DA for 1 hour. ***p < 0.001 compared to the Con-KD cells treated with a vehicle; ###p < 0.001 compared to the cells transfected with WT-GRK2 and treated with vehicle; $$$p < 0.001 compared to other 4KR-GRK2 groups (n = 3). (D)Con-KD and arrestin2/3-KD HEK-293 cells were transfected with D2R (1.5 – 1.7 pmol/mg protein) along with a mock vector, WT- or NLSX-arrestin3. Cells were pretreated with a vehicle, 3 mM MβCD for 30 minutes, or 200 μM MDC for 20 minutes, followed by treatment with 10 μM DA for 1 hour. ***p < 0.001 compared to vehicle-treated group of Con-KD cells; ##p < 0.01 compared to the vehicle-treated cells expressing WT-arrestin3; $p < 0.05, $$p < 0.01 compared to corresponding vehicle- and MDC-treated cells (n = 3).
Preprints 150146 g007
Preprints 150146 g008
Figure 8. Ubiquitination-mediated interactions between arrestin3 and GRK2 govern their selective roles in different endocytic pathways. (A)HEK-293 cells were transfected with D2R along with FLAG-tagged WT-arrestin3 or NLSX-arrestin3. Cells were treated with 10 μM DA for 2 minutes. Lysates were immunoprecipitated with FLAG beads. Co-IP/lysates and IP were immunoblotted with antibodies against endogenous CHC/Cav1 and FLAG, respectively. **p < 0.01, ##p < 0.01 compared to corresponding vehicle-treated groups (n = 3). (B)HEK-293 cells were transfected with D2R along with FLAG-tagged WT-GRK2 or 4KR-GRK2. Cells were treated with 10 μM DA for 2 minutes. Lysates were immunoprecipitated with FLAG beads. Co-IP/lysates and IP were immunoblotted with antibodies against endogenous CHC/Cav1 and FLAG, respectively. **p < 0.01 compared to corresponding 2 min groups (n = 3). (C)HEK-293 cells were transfected with D2R and FLAG-tagged β2 adaptin (β2-ad) along with a mock vector, GFP-tagged WT-arrestin3 or K11/12R-arrestin3. Cells were treated with 10 μM DA for 2 minutes. Lysates were immunoprecipitated with FLAG beads. Co-IP/lysates and IP were blotted with antibodies against GFP and FLAG, respectively. **p < 0.01 compared to corresponding Veh groups (n = 3). (D)HEK-293 cells were transfected with D2R and FLAG-β2-ad along with a mock vector, WT-GRK2, or 4KR-GRK2. Cells were treated with 10 μM DA for 2 minutes. Lysates were immunoprecipitated with FLAG beads. Co-IP/lysates and IP were blotted with antibodies against GRK2 and FLAG, respectively. **p < 0.01 compared to other groups (n = 3).
Figure 8. Ubiquitination-mediated interactions between arrestin3 and GRK2 govern their selective roles in different endocytic pathways. (A)HEK-293 cells were transfected with D2R along with FLAG-tagged WT-arrestin3 or NLSX-arrestin3. Cells were treated with 10 μM DA for 2 minutes. Lysates were immunoprecipitated with FLAG beads. Co-IP/lysates and IP were immunoblotted with antibodies against endogenous CHC/Cav1 and FLAG, respectively. **p < 0.01, ##p < 0.01 compared to corresponding vehicle-treated groups (n = 3). (B)HEK-293 cells were transfected with D2R along with FLAG-tagged WT-GRK2 or 4KR-GRK2. Cells were treated with 10 μM DA for 2 minutes. Lysates were immunoprecipitated with FLAG beads. Co-IP/lysates and IP were immunoblotted with antibodies against endogenous CHC/Cav1 and FLAG, respectively. **p < 0.01 compared to corresponding 2 min groups (n = 3). (C)HEK-293 cells were transfected with D2R and FLAG-tagged β2 adaptin (β2-ad) along with a mock vector, GFP-tagged WT-arrestin3 or K11/12R-arrestin3. Cells were treated with 10 μM DA for 2 minutes. Lysates were immunoprecipitated with FLAG beads. Co-IP/lysates and IP were blotted with antibodies against GFP and FLAG, respectively. **p < 0.01 compared to corresponding Veh groups (n = 3). (D)HEK-293 cells were transfected with D2R and FLAG-β2-ad along with a mock vector, WT-GRK2, or 4KR-GRK2. Cells were treated with 10 μM DA for 2 minutes. Lysates were immunoprecipitated with FLAG beads. Co-IP/lysates and IP were blotted with antibodies against GRK2 and FLAG, respectively. **p < 0.01 compared to other groups (n = 3).
Preprints 150146 g008
Preprints 150146 g009
Figure 9. Summary of the relationship between Mmd2-mediated ubiquitination of GRK2/arrestin3 and endocytic pathways. Both GRK2 and arrestin3, when ubiquitinated, regulate clathrin-mediated endocytosis (CME). Distinct protein interactions determine the pathway specificity: Ub-arrestin3 binds to clathrin heavy chain (CHC), while Ub-GRK2 interacts with adaptor protein 2 (AP2). When non-ubiquitinated, these proteins control different endocytic pathways - GRK2 mediates caveolar endocytosis through its interaction with Cav1, whereas arrestin3, which lacks Cav1 binding capability, regulates a distinct third endocytic pathway that remains to be characterized. Protein interactions depicted by arrows connected with solid lines dictate the endocytic pathway (endocytic code interaction), while arrows linked by dotted lines represent protein interactions that have a supporting role (accessory interaction).
Figure 9. Summary of the relationship between Mmd2-mediated ubiquitination of GRK2/arrestin3 and endocytic pathways. Both GRK2 and arrestin3, when ubiquitinated, regulate clathrin-mediated endocytosis (CME). Distinct protein interactions determine the pathway specificity: Ub-arrestin3 binds to clathrin heavy chain (CHC), while Ub-GRK2 interacts with adaptor protein 2 (AP2). When non-ubiquitinated, these proteins control different endocytic pathways - GRK2 mediates caveolar endocytosis through its interaction with Cav1, whereas arrestin3, which lacks Cav1 binding capability, regulates a distinct third endocytic pathway that remains to be characterized. Protein interactions depicted by arrows connected with solid lines dictate the endocytic pathway (endocytic code interaction), while arrows linked by dotted lines represent protein interactions that have a supporting role (accessory interaction).
Preprints 150146 g009
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
bsky
MDPI Initiatives
Important Links
Subscribe

Accessibility

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2026 MDPI (Basel, Switzerland) unless otherwise stated